Idarucizumab is the first reversal agent approved for the direct thrombin inhibitor dabigatran. The authors summarize the findings from the clinical trial series and describe case reports, post-marketing data, and ongoing studies.
Keywords: Pradaxa; Praxbind; anticoagulation; dabigatran; idarucizumab; reversal agent.